Recent research have focused on the intersection of GLP-1|GIP|glucagon receptor agonist therapies and DA neurotransmission. While GLP activators are widely employed for addressing type 2 T2DM, their emerging impacts on https://marvinywgp669067.blog5.net/93384974/novel-gcgr-stimulators-and-dopamine-influence-a-comparative-copyrightination